<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9684">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692661</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-BCa2022-01</org_study_id>
    <nct_id>NCT05692661</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer</brief_title>
  <official_title>A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer After Breast Conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant radiotherapy is the standard treatment for early breast cancer after breast&#xD;
      conserving surgery. Molecular subtypes was significantly associated with the risk of local&#xD;
      recurrence of breast cancer. Nguyen et al found that the overall 5-year cumulative incidence&#xD;
      of local recurrence was 0.8% for luminal A, 1.5% for luminal B, 8.4% for HER2 positive, and&#xD;
      7.1% for triple negative breast cancer after lumpectomy and radiotherapy. Her2 positive and&#xD;
      triple negative breast cancers may be inherently radioresistant.&#xD;
&#xD;
      Therefore, for HER2 positive and triple negative breast cancer with high local recurrence and&#xD;
      radiation resistance, proton combined with carbon ion is proposed after breast conserving&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2023</start_date>
  <completion_date type="Anticipated">January 10, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>3 months after the completion of CIRT</time_frame>
    <description>Treatment related acute toxicity assessed by CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local regional recurrence</measure>
    <time_frame>within 5 years after radiotherapy.</time_frame>
    <description>The Ipsilateral breast and regional lymph nodes recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome as measured by Breast Cancer Treatment Outcomes Scale</measure>
    <time_frame>within 5 years after radiotherapy.</time_frame>
    <description>Cosmetic outcome will be evaluated by Breast Cancer Treatment Outcomes Scale filled out by patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome as measured by BCCT.core software</measure>
    <time_frame>within 5 years after radiotherapy.</time_frame>
    <description>Patients' photographs of the breasts will be taken. With the use of BCCT.core software from The Breast Research group (INESC TEC) cosmetic outcome will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>proton plus carbon ion radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTV1: whole breast, proton therapy. CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>proton plus carbon ion radiotherapy</intervention_name>
    <description>CTV1: whole breast, 40.05Gy(RBE) in 15 fractions with proton ion therapy; CTVboost: Tumor bed, carbon ion dose escalation study with four dose levels [10.2Gy(RBE)/3Fx,10.8Gy(RBE) /3Fx,11.4Gy(RBE)/3Fx and 12Gy(RBE)/3Fx ].</description>
    <arm_group_label>proton plus carbon ion radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed HER2 positive or Triple Negative invasive breast&#xD;
             carcinoma.(HER2 positive: immunohistochemistry [IHC] 3+ and or fluorescence in situ&#xD;
             hybridization [FISH] amplified; Triple Negative: estrogen receptor [ER] and&#xD;
             progesterone receptor [PR] &lt; 1%, HER2 negative [IHC 1+ or 2+ FISH non-amplified])&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 80 years.&#xD;
&#xD;
          -  The primary tumor must be excised via breast conserving surgery.&#xD;
&#xD;
          -  Stage p T1-2 N0 M0&#xD;
&#xD;
          -  ECOG performance status ≤2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Invasive breast cancer not confirmed by pathology.&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Prior thoracic radiation.&#xD;
&#xD;
          -  Pregnancy or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <phone>+86 021-38296666</phone>
      <email>ping.li@sphic.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>January 11, 2023</last_update_submitted>
  <last_update_submitted_qc>January 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Qing Zhang,MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2 Positive</keyword>
  <keyword>Triple Negative</keyword>
  <keyword>Proton and Carbon Ion</keyword>
  <keyword>Dose Escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

